Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Oncol. 2007 Apr;34(2):165-72.

Immunotherapeutic strategies for high-risk bladder cancer.

Author information

  • 1Department of Genitourinary Medical Oncology and Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. padsharma@mdanderson.org

Abstract

Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-grade superficial disease. The nonspecific immune modulation that occurs as a result of BCG therapy is not well understood; however, the success of BCG therapy provides a basis for the exploration of mechanisms related to immune responses and the development of novel immunotherapeutic agents for the treatment of high-risk disease. In this review, we discuss the complexity of the immune system and therapies that are considered capable of manipulating it to potentially benefit patients with bladder cancer.

PMID:
17382800
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk